Jazz Pharmaceuticals Plc - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on January 2, 2009, by Jazz Pharmaceuticals, Inc. (Delaware). The report addresses a specific event occurring on December 31, 2008, regarding the company's debt obligations.
Key Financial Metrics and Debt Status
- Debt Instrument: $119 million principal amount of senior secured notes.
- Missed Payment: Approximately $4.5 million quarterly interest payment due December 31, 2008.
- Default Status: The failure to pay constitutes an event of default under the Senior Secured Note and Warrant Purchase Agreement dated March 14, 2008.
- Penalty Interest: Interest accrues at the regular rate plus an additional 2% due to non-payment.
- Liquidity/Cash Flow: The filing does not provide specific cash flow or liquidity figures, only the fact of the missed payment.
Material Changes and Events
The primary material change is the declaration of default on the senior secured notes. On January 8, 2009, the Company received a formal notice of default. While the default permits Majority Holders (holding at least 50% of the Notes) to accelerate payment, the Company has not yet received an acceleration notice.
Management Commentary and Risks
Management states that the Company has been working with the Collateral Agent and Purchasers to resolve the matter prior to and since the due date. The Company intends to continue seeking a resolution. The primary risk identified is the potential acceleration of the $119 million debt obligation by Majority Holders.
Investor Verification Checklist
- Confirm whether an acceleration notice has been issued by Majority Holders since January 8, 2009.
- Verify the current status of negotiations with the Collateral Agent and Purchasers regarding the $4.5 million missed payment.
- Assess the Company's current cash position and ability to meet future interest obligations or principal repayment if accelerated.
- Review the terms of the Loan Agreement regarding the 2% penalty interest accrual.